-
2
-
-
0025751644
-
Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors
-
HELLSTRAND K, HERMODSSON S. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors. Scand J Immunol 1991: 34: 741-750.
-
(1991)
Scand J Immunol
, vol.34
, pp. 741-750
-
-
Hellstrand, K.1
Hermodsson, S.2
-
3
-
-
0028113354
-
Histaminergic regulation of natural killer cells: Role of monocyte-derived, reactive oxygen metabolites
-
HELLSTRAND K, ASEA A, DAHLGREN C, HERMODSSON S. Histaminergic regulation of natural killer cells: role of monocyte-derived, reactive oxygen metabolites. J Immunol 1994: 153: 4940-4947.
-
(1994)
J Immunol
, vol.153
, pp. 4940-4947
-
-
Hellstrand, K.1
Asea, A.2
Dahlgren, C.3
Hermodsson, S.4
-
4
-
-
0030017683
-
Histaminergic regulation of interferon-γ production by human natural killer cells
-
ASEA A, HANSSON M, HOUZE T, et al. Histaminergic regulation of interferon-γ production by human natural killer cells. Clin Exp Immunol 1996: 105: 376-382.
-
(1996)
Clin Exp Immunol
, vol.105
, pp. 376-382
-
-
Asea, A.1
Hansson, M.2
Houze, T.3
-
5
-
-
0030039450
-
Induction of apoptosis by monocyte-derived, reactive oxygen metabolites
-
HANSSON M, ASEA A, HERMODSSON S, HELLSTRAND K. Induction of apoptosis by monocyte-derived, reactive oxygen metabolites. J Immunol 1996: 156: 1-7.
-
(1996)
J Immunol
, vol.156
, pp. 1-7
-
-
Hansson, M.1
Asea, A.2
Hermodsson, S.3
Hellstrand, K.4
-
6
-
-
0030018066
-
Histaminergic regulation of natural killer cells: Protection against monocyte-induced apoptosis
-
HANSSON M, ASEA A, HERMODSSON S, HELLSTRAND K. Histaminergic regulation of natural killer cells: protection against monocyte-induced apoptosis. Scand J Immunol 1996: 44: 193-196.
-
(1996)
Scand J Immunol
, vol.44
, pp. 193-196
-
-
Hansson, M.1
Asea, A.2
Hermodsson, S.3
Hellstrand, K.4
-
7
-
-
0029980720
-
Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia
-
BRUNE M, HELLSTRAND K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukemia. Br J Haematol 1996: 92: 620-626.
-
(1996)
Br J Haematol
, vol.92
, pp. 620-626
-
-
Brune, M.1
Hellstrand, K.2
-
8
-
-
0025614624
-
Role of histamine in natural killer cell-mediated resistance against tumor cells
-
HELLSTRAND K, ASEA A, HERMODSSON S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol 1990: 145: 4365-4370.
-
(1990)
J Immunol
, vol.145
, pp. 4365-4370
-
-
Hellstrand, K.1
Asea, A.2
Hermodsson, S.3
-
9
-
-
0030027630
-
Histaminergic regulation of natural killer cell-mediated clearance of tumor cells in vivo
-
ASEA A, HERMODSSON S, HELLSTRAND K. Histaminergic regulation of natural killer cell-mediated clearance of tumor cells in vivo. Scand J Immunol 1996: 43: 9-15.
-
(1996)
Scand J Immunol
, vol.43
, pp. 9-15
-
-
Asea, A.1
Hermodsson, S.2
Hellstrand, K.3
-
10
-
-
85086609532
-
Role of histamine in natural killer cell-dependent defence against herpes simplex virus type 2 infection in mice
-
HELLSTRAND K, ASEA A, HERMODSSON S. Role of histamine in natural killer cell-dependent defence against herpes simplex virus type 2 infection in mice. Clin Diagn Lab Immunol 1995: 2: 3-6.
-
(1995)
Clin Diagn Lab Immunol
, vol.2
, pp. 3-6
-
-
Hellstrand, K.1
Asea, A.2
Hermodsson, S.3
-
11
-
-
0022974575
-
Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells
-
OSHIMI K, OSHIMI Y, AKUTSI M, SAITO H, OKADA M, MIZOGUCHI H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986: 68: 938-948.
-
(1986)
Blood
, vol.68
, pp. 938-948
-
-
Oshimi, K.1
Oshimi, Y.2
Akutsi, M.3
Saito, H.4
Okada, M.5
Mizoguchi, H.6
-
12
-
-
0023104794
-
Induction of NK cell activity against fresh human leukemia in culture with interleukin 2
-
LOTZOVÀ E, SAVARY CA, HERBERMAN RB. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 1987: 138: 2718-2727.
-
(1987)
J Immunol
, vol.138
, pp. 2718-2727
-
-
Lotzovà, E.1
Savary, C.A.2
Herberman, R.B.3
-
13
-
-
0025881465
-
Inducibility of lymphokine-activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance
-
ARCHIMBAUD E, BAILLY M DORÉ JF. Inducibility of lymphokine-activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br J Haematol 1991: 77: 328-334.
-
(1991)
Br J Haematol
, vol.77
, pp. 328-334
-
-
Archimbaud, E.1
Bailly, M.2
Doré, J.F.3
-
14
-
-
0028216550
-
In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: Correlation with the rate and duration of complete remission and with survival
-
LAURIA F, RASPADORI D, RONDELLI D, VENTURA MA, FOA R. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994: 8: 724-728.
-
(1994)
Leukemia
, vol.8
, pp. 724-728
-
-
Lauria, F.1
Raspadori, D.2
Rondelli, D.3
Ventura, M.A.4
Foa, R.5
-
15
-
-
0025908320
-
Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: A pilot study
-
FOA R, MELONI G, TOSTI S, et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol 1991: 77: 491-496.
-
(1991)
Br J Haematol
, vol.77
, pp. 491-496
-
-
Foa, R.1
Meloni, G.2
Tosti, S.3
-
16
-
-
0025615912
-
Recombinant IL-2 for acute myeloid leukemia in first complete remission: A pilot study
-
MACDONALD D, JIANG YZ, GORDON AA. Recombinant IL-2 for acute myeloid leukemia in first complete remission: a pilot study. Leuk Res 1990: 14: 967-973.
-
(1990)
Leuk Res
, vol.14
, pp. 967-973
-
-
Macdonald, D.1
Jiang, Y.Z.2
Gordon, A.A.3
-
17
-
-
0002132336
-
Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse
-
SHEPHERD JD, JACKY E, GRATHWOHL A, et al. Phase II study of subcutaneous rHu IL-2 in patients with acute myelogenous leukemia in partial or complete second remission and partial relapse. Br J Haematol 1994: S87, 205.
-
(1994)
Br J Haematol
, vol.S87
, pp. 205
-
-
Shepherd, J.D.1
Jacky, E.2
Grathwohl, A.3
-
18
-
-
0028299792
-
Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells
-
HELLSTRAND K, ASEA A, HERMODSSON S. Histaminergic regulation of antibody-dependent cellular cytotoxicity of granulocytes, monocytes, and natural killer cells, J Leukocyte Biol 1994: 55: 393-397.
-
(1994)
J Leukocyte Biol
, vol.55
, pp. 393-397
-
-
Hellstrand, K.1
Asea, A.2
Hermodsson, S.3
-
19
-
-
0023063418
-
Histamine modulation of lymphocyte biology: Membrane receptors, signal transduction, and functions
-
BEER DJ, ROCKLIN RE. Histamine modulation of lymphocyte biology: membrane receptors, signal transduction, and functions. Crit Rev Immunol 1987: 7: 55-101.
-
(1987)
Crit Rev Immunol
, vol.7
, pp. 55-101
-
-
Beer, D.J.1
Rocklin, R.E.2
|